Adamis Pharmaceuticals' Prostate Cancer Drug APC-100 Granted a Patent in US
Published: Jul 21, 2011
SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP.OB), today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States. A patent entitled “Chroman-Derived Compounds for the Treatment of Cancer” has been issued. This patent, together with earlier issued European and US patents, significantly strengthens the Adamis APC-100 patent portfolio for the use of APC-100 in the treatment of early and late stage prostate cancer. Claims include a method of: i.) inhibiting the growth of prostate cancer cells; ii.) delaying the progression of prostate cancer; and, iii.) preventing the recurrence of prostate cancer.